Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

CompletedOBSERVATIONAL
Enrollment

156

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

December 30, 2024

Study Completion Date

December 31, 2024

Conditions
Psychosis
Interventions
DRUG

Patients with psychosis will be treated with known antipsychotic medication

Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.

Trial Locations (1)

35294

Sparks Center, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT03442101 - Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study | Biotech Hunter | Biotech Hunter